Skip to main content
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

COVID-19 Jab Trial Data to Be Publicly Available at Greatly Accelerated Rate

A federal judge in Texas ordered the U.S. Food and Drug Administration (FDA) to greatly accelerate its release of COVID-19 jab trial data.

The FDA, Pfizer and Moderna want to keep data hidden from the public for decades.

However, U.S. District Judge Mark Pittman won’t allow the pharmaceutical companies to hide it secrets from Americans much longer.

Pittman ordered data on Moderna’s COVID-19 jab for adults and Pfizer’s COVID-19 jab for children to be made publicly available in roughly two years.

The FDA intended to slowly release this data to the public over 23.5 years.

NTD reported:

In a decision hailed as a win for transparency by the lawyer representing the plaintiffs (the parents of a child injured by a COVID-19 vaccine) in a lawsuit (pdf) against the FDA, the Texas judge ordered the FDA to produce the data about ten times faster than the agency wanted.

“Democracy dies behind closed doors,” is how U.S. District Judge Mark Pittman opened his order (pdf), issued on May 9, which requires the FDA to produce the data on Moderna’s and Pfizer’s COVID-19 vaccines at an average rate of at least 180,000 pages per month.

The FDA had argued it would be “impractical” to release the estimated 4.8 million pages at more than between 1,000 and 16,000 pages per month, which would have taken at least 23.5 years.

Aaron Siri of Siri & Glimstad, who represents the plaintiffs in the legal action against the FDA, called the decision “another blow for transparency and accountability” that builds on an earlier court order targeting Pfizer’s COVID-19 vaccine data for those aged 16 and older.

Just the News added:

Judge Pittman’s latest order requires the FDA to produce all of its data on Pfizer’s vaccine for 12- to 15-year-olds and Moderna’s vaccine for adults by June 30, 2025.

While the judge acknowledged that the court is aware of the FDA’s limited resources dedicated to freedom of information requests (FOIA), he stated that “the number of resources an agency dedicates to such requests does not dictate the bounds of an individual’s FOIA rights.”

“Instead, the Court must ensure that the fullest possible disclosure of the information sought is timely provided — as ‘stale information is of little value,'” Pittman wrote.

Read the order below:


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Leave a comment
Thanks for sharing!